Skip to search formSkip to main contentSkip to account menu

lesinurad

Known as: {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

RDEA594Zurampic

Broader (3)

ThioglycolatesTriazolesUricosuric Agents
Urate Transporter 1 Inhibitors [MoA]lesinurad 200 MG

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Abstract The objectives of this study were to determine the absolute bioavailability of lesinurad and to characterized its… 
2018
2018
Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
Lesinurad [Zurampic; 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)], a selective inhibitor of uric acid… 
2017
2017
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide
Lesinurad is a selective uric acid reabsorption inhibitor approved for the treatment of hyperuricemia associated with gout in… 
2017
2017
The development of an effective synthetic route of lesinurad (RDEA594)
BackgroundLesinurad is a novel selective uric acid salt transport protein 1 (URAT1) inhibitor which is approved in the USA for… 
Review
2016
Review
2016
Lesinurad: A significant advancement or just another addition to existing therapies of gout?
Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in… 
2015
2015
FRI0320 Lesinurad, A Selective URIC Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care…
Background Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for treatment of gout in… 
2015
2015
FRI0333 Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care…
Background Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for treatment of gout in… 
2015
2015
SAT0313 Relationship Between Sustained Lowering of Serum Urate Levels and Improvements in Gout Flares and Tophus Area: Pooled Exploratory Analysis of Gout Subjects Receiving Lesinurad and Xanthine…
Background Previous studies have shown that long-term urate-lowering therapy is required for improvements in gout flare frequency… 
2014
2014
Gout: a disease of the past, the present, but not the future?
2013
2013
FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo…
Background Lesinurad (LESUR) is an oral investigational URAT1 inhibitor for the treatment of gout. A Phase 2B study in 208 gout… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)